CIM
EBS icon

CIM Investment Management’s Emergent Biosolutions EBS Stock Holding History

CIM Investment Management’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-4,741
Closed -$206K – 266
2021
Q4 		$206K Hold
4,741
– – 0.06% 284
2021
Q3 		$237K Hold
4,741
– – 0.07% 244
2021
Q2 		$299K Hold
4,741
– – 0.09% 206
2021
Q1 		$440K Sell
4,741
-283
-6% -$29K 0.14% 150
2020
Q4 		$450K Buy
+5,024
New +$461K 0.15% 142
2020
Q3 		– Sell
-3,868
Closed -$306K – 264
2020
Q2 		$306K Buy
+3,868
New +$288K 0.12% 168

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

CIM Investment Management's EBS Position: Q1 2022 in Review

CIM Investment Management sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 4,741 shares — an estimated $206K sold.

CIM Investment Management first reported a position in EBS in Q2 2020 and held it in 6 quarters. The position peaked at $450K in Q4 2020. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

  • CIM Investment Management reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
  • CIM Investment Management sold 4,741 Emergent Biosolutions shares in Q1 2022, an estimated $206K.
  • CIM Investment Management first reported a position in Emergent Biosolutions in Q2 2020 and held it in 6 quarters.
  • CIM Investment Management's Emergent Biosolutions position peaked at $450K in Q4 2020.
  • 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on CIM Investment Management's 13F filing for Q1 2022, filed 17 May 2022.